Scientists have identified a group of drugs that appear to reduce or eliminate certain childhood brain cancers while sparing normal brain tissue. []
Scientists have identified a group of drugs that appear to reduce or eliminate certain childhood brain cancers while sparing normal brain tissue. []

Scientists at Huntsman Cancer Institute (HCI) at the University of Utah write in Cell Reports (“MEK Inhibitors Reverse Growth of Embryonal Brain Tumors Derived from Oligoneural Precursor Cells”) that they have identified an existing group of drugs that appear to reduce or eliminate a certain subgroup of childhood brain cancers while sparing normal brain tissue. The research was conducted using a new zebrafish animal model system developed by the researchers that closely resembles an aggressive subtype of pediatric brain tumors.

“For many pediatric brain tumors, no cell or animal model exists to test targeted, or personalized, medications that could significantly improve survival and alleviate the harmful side effects of conventional therapies,” explains Rodney Stewart, Ph.D., an assistant professor in the Department of Oncological Sciences at the University of Utah and an HCI investigator. “Indeed, children with rare brain tumors have few options for life-saving treatment. Our hope is by creating this animal model we will be a step closer to finding effective therapies.”

The researchers studied a particularly aggressive pediatric brain tumor, known as primitive neuroectodermal tumors of the central nervous system (CNS-PNET), for which few animal or cell line models exist. Without an animal model or cell lines, Stewart explained, treatments could not be tested. Over the course of 7 years, Dr. Stewart and his team worked to develop a model that, at the genomic level, closely modeled the human condition they hoped to study.

“We spent a lot of time comparing brain tumors arising in fish with related human brain cancers at the molecular genetic level,” he says. “This is important because these childhood brain cancers are rare, and as a result, there are few patient samples to study for comparisons.”

Human tissue samples were necessary, however, to construct a reliable model. “We needed to reach out to several groups,” Dr. Stewart explains, including Primary Children's Hospital in Salt Lake City and The Hospital for Sick Children in Toronto. He credits discoveries announced by two other groups studying similar cancers that opened the way for his team to move forward. “They were able to reclassify CNS-PNET tumors into distinct subgroups at the molecular level. That opened up a new avenue for our team because that stratification made it possible for us to really nail down what the zebrafish brain tumor model represents.” 

Using the model, Dr. Stewart's lab was able to test already existing compounds to see if they could find a targeted therapy that would work on one of the newly identified subgroups—the oligoneural or NB_FOXR2 CNS-PNET subgroup. Through work they had done to create the tumor model, they knew that a particular drug already in human clinical trials might work.

“When we treated the fish with MEK inhibitors, they exhibited a remarkable response,” says Dr. Stewart. “Not only was the tumor burden reduced, it completely eliminated the tumor in about 80% of the fish, and those tumors have not come back. This is a durable response from a transient treatment. It's what we look for in cancer therapy, an effective drug that can be taken for a certain amount of time but, after the cancer is gone, patients can stop taking the drug and go on living their lives.”

Dr. Stewart is careful to emphasize that while the brain tumor type between fish and humans is similar, more studies are needed to determine if the results can be translated into the clinic. He would like to see his discovery in the hands of physicians as soon as possible. “Currently, the outcome for children with these cancers is deplorable. We don't want to wait much longer,” he says.

Previous articleCRISPR/Cas9 Cell Therapeutics – The Next Generation of Cures
Next articleAllergan to Acquire Motus Therapeutics